Small molecule · Inhibitor of PRMT5 · developed by Prelude Therapeutics
PRT811 is an orally available small molecule that selectively binds and inhibits PRMT5, a type II methyltransferase that forms monomethylarginine and symmetric dimethylarginine on histones and other proteins. Inhibition reduces methylated arginine on histones H2A, H3 and H4, altering expression of genes that govern cellular proliferation. It is being studied in advanced solid tumors and recurrent glioma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04089449 | Phase 1 | Advanced Solid Tumor | Completed | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorRecurrent Glioma
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →